Clinical features of patients with metastatic pheochromocytoma/paraganglioma
Objective: To analyze the clinical features of patients with metastatic pheochromocytoma/paraganglioma (PPGL). Methods: A follow-up study. The clinical data of 250 patients with metastatic PPGL treated at Peking Union Medical College Hospital from January 2018 to August 2023 were retrospectively analyzed, including 124 males and 126 females. The clinical features and treatment status of patients with metastatic PPGL were summarized and analyzed. Kaplan-Meier survival curve was used to evaluate patients' prognosis. Results: The age of onset, age of diagnosis, and age of tumor metastasis in patients with metastatic PPGL were (33.1±14.2) years, (35.4±15.2) years, and (40.7±15.3) years, respectively. Metastasis occurred in 26.4%(66/250) of patients at the time of initial diagnosis. Among patients without metastases at the time of initial diagnosis, the time from primary tumor resection to metastasis[M(Q1, Q3)] was 5.0 (3.0, 9.0) years, among which 20.1%(37/184) of patients had metastases more than 10 years after surgery. Most patients showed increased 24-hour urinary norepinephrine and plasma normetanephrine, accounting for 78.2%(176/225) and 78.7%(85/108), respectively. 42.3%(69/163) of patients had increased neuron specific enolase (NSE)levels. Germline mutations were screened in 201 patients, of which 55.2%(111/201) had germline pathogenic mutations. In patients with gene mutations, 76.5%(85/111) had SDHB mutations. 52.0%(130/250) of metastatic PPGL patients had primary sites outside the adrenal gland, with the Ki-67 index of 5% (3%, 8%). There were 85.6%(214/250) patients had multisystem metastasis, with bone metastasis being the most common site of metastasis, accounting for 60.8%(152/250). In terms of treatment, 32.8%(75/229) of patients underwent two treatment regimens and 8.7%(20/229) of patients underwent three treatment regimens. Most patients had a good prognosis, with a 5-year and 10-year survival rate of 88.0% and 84.0%, respectively. However, some patients had rapid disease progression, and as of August 2023, 30 patients died, and the time from diagnosis to death in deceased patients was 2.0 (1.0, 4.0) years. Conclusions: Patients with metastatic PPGL have a high rate of germline mutations, especially those with SDHB mutations. The metastatic PPGL is usually multisystem metastasis with the characteristics of mostly paraganglioma, large lesion diameter and high Ki-67 index.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:104 |
---|---|
Enthalten in: |
Zhonghua yi xue za zhi - 104(2024), 14 vom: 09. Apr., Seite 1174-1179 |
Sprache: |
Chinesisch |
---|
Beteiligte Personen: |
Cui, Y Y [VerfasserIn] |
---|
Links: |
---|
Themen: |
EC 1.3.99.1 |
---|
Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.3760/cma.j.cn112137-20230820-00271 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370724585 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370724585 | ||
003 | DE-627 | ||
005 | 20240408233253.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240407s2024 xx |||||o 00| ||chi c | ||
024 | 7 | |a 10.3760/cma.j.cn112137-20230820-00271 |2 doi | |
028 | 5 | 2 | |a pubmed24n1369.xml |
035 | |a (DE-627)NLM370724585 | ||
035 | |a (NLM)38583049 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a chi | ||
100 | 1 | |a Cui, Y Y |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical features of patients with metastatic pheochromocytoma/paraganglioma |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.04.2024 | ||
500 | |a Date Revised 08.04.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Objective: To analyze the clinical features of patients with metastatic pheochromocytoma/paraganglioma (PPGL). Methods: A follow-up study. The clinical data of 250 patients with metastatic PPGL treated at Peking Union Medical College Hospital from January 2018 to August 2023 were retrospectively analyzed, including 124 males and 126 females. The clinical features and treatment status of patients with metastatic PPGL were summarized and analyzed. Kaplan-Meier survival curve was used to evaluate patients' prognosis. Results: The age of onset, age of diagnosis, and age of tumor metastasis in patients with metastatic PPGL were (33.1±14.2) years, (35.4±15.2) years, and (40.7±15.3) years, respectively. Metastasis occurred in 26.4%(66/250) of patients at the time of initial diagnosis. Among patients without metastases at the time of initial diagnosis, the time from primary tumor resection to metastasis[M(Q1, Q3)] was 5.0 (3.0, 9.0) years, among which 20.1%(37/184) of patients had metastases more than 10 years after surgery. Most patients showed increased 24-hour urinary norepinephrine and plasma normetanephrine, accounting for 78.2%(176/225) and 78.7%(85/108), respectively. 42.3%(69/163) of patients had increased neuron specific enolase (NSE)levels. Germline mutations were screened in 201 patients, of which 55.2%(111/201) had germline pathogenic mutations. In patients with gene mutations, 76.5%(85/111) had SDHB mutations. 52.0%(130/250) of metastatic PPGL patients had primary sites outside the adrenal gland, with the Ki-67 index of 5% (3%, 8%). There were 85.6%(214/250) patients had multisystem metastasis, with bone metastasis being the most common site of metastasis, accounting for 60.8%(152/250). In terms of treatment, 32.8%(75/229) of patients underwent two treatment regimens and 8.7%(20/229) of patients underwent three treatment regimens. Most patients had a good prognosis, with a 5-year and 10-year survival rate of 88.0% and 84.0%, respectively. However, some patients had rapid disease progression, and as of August 2023, 30 patients died, and the time from diagnosis to death in deceased patients was 2.0 (1.0, 4.0) years. Conclusions: Patients with metastatic PPGL have a high rate of germline mutations, especially those with SDHB mutations. The metastatic PPGL is usually multisystem metastasis with the characteristics of mostly paraganglioma, large lesion diameter and high Ki-67 index | ||
650 | 4 | |a English Abstract | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Ki-67 Antigen |2 NLM | |
650 | 7 | |a Succinate Dehydrogenase |2 NLM | |
650 | 7 | |a EC 1.3.99.1 |2 NLM | |
700 | 1 | |a Zhou, Y |e verfasserin |4 aut | |
700 | 1 | |a Gao, Y J |e verfasserin |4 aut | |
700 | 1 | |a Li, T Y |e verfasserin |4 aut | |
700 | 1 | |a Wang, Y |e verfasserin |4 aut | |
700 | 1 | |a Zhang, W Q |e verfasserin |4 aut | |
700 | 1 | |a Zhou, T |e verfasserin |4 aut | |
700 | 1 | |a Chen, S |e verfasserin |4 aut | |
700 | 1 | |a Tong, A L |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Zhonghua yi xue za zhi |d 1994 |g 104(2024), 14 vom: 09. Apr., Seite 1174-1179 |w (DE-627)NLM000566861 |x 0376-2491 |7 nnns |
773 | 1 | 8 | |g volume:104 |g year:2024 |g number:14 |g day:09 |g month:04 |g pages:1174-1179 |
856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112137-20230820-00271 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 104 |j 2024 |e 14 |b 09 |c 04 |h 1174-1179 |